Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Perisson, R. Epaud, M. Fayon, N. Nathan, G. Thouvenin, H. Corvol, A. Clement, RespiRare Group (Paris, Creteil, Bordeaux, France). Beneficial effect of azithromycin in children with diffuse parenchymal lung disease. Eur Respir J 2014; 44: Suppl. 58, 3495

Member's Comments

No comment yet.

Related content which might interest you: Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 6 Year: 2014 Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 5 Year: 2014 The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Clinical features of four children with pulmonary alveolar proteinosis Source: International Congress 2014 – ILDs 5 Year: 2014 The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital Source: International Congress 2014 – ILDs 4 Year: 2014 Aetiological panorama in the diagnosis of interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Clinical course and outcome of vasculitis related interstitial lung disease Source: International Congress 2014 – ILDs 2 Year: 2014 Cystic lung disease with pulmonary amyloidosis: Analysis of 21 patients Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Morality predictors in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014 Airway centered interstitial fibrosis – An under-recognized type of idiopathic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 "Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease" Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Management of spontaneous pneumothorax in patients with or without Birt-Hogg-Dubé syndrome Source: International Congress 2014 – ILDs 1 Year: 2014 Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy Source: International Congress 2014 – ILDs 4 Year: 2014 Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014